Hhlr Advisors, Ltd. I Mab Transaction History
Hhlr Advisors, Ltd.
- $4.36 Billion
- Q3 2024
A detailed history of Hhlr Advisors, Ltd. transactions in I Mab stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 6,909,220 shares of IMAB stock, worth $6.36 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
6,909,220
Previous 6,909,220
-0.0%
Holding current value
$6.36 Million
Previous $11.5 Million
25.75%
% of portfolio
0.2%
Previous 0.3%
Shares
5 transactions
Others Institutions Holding IMAB
# of Institutions
36Shares Held
15.5MCall Options Held
56.4KPut Options Held
5.8K-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$3.83 Million3.04% of portfolio
-
Boothbay Fund Management, LLC New York, NY1.42MShares$1.31 Million0.05% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U0567KShares$521,3180.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny499KShares$459,3560.0% of portfolio
-
Two Sigma Investments, LP New York, NY409KShares$375,8370.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $76.5M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...